Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Vinita Akula ^{[1
]}

Lily Chen ^{[1
]}

Yusuf Acikgoz ^{[2
]}

Katherine Klein ^{[1
]}

Betul Gok Yavuz ^{[3
]}

Lokman Cevik ^{[4
]}

Tarik Demir ^{[5
]}

Ashish Manne ^{[2
]}

Ilyas Sahin ^{[6
]}

Ahmed Kaseb ^{[7
]}

Elshad Hasanov ^{[2
]}

机构：

[1] The University of Texas Health Science Center at Houston (UTHealth),Department of Internal Medicine

[2] The Ohio State University Comprehensive Cancer Center,Division of Medical Oncology, Department of Internal Medicine

[3] University of Missouri,Department of Medicine

[4] The Ohio State University Wexner Medical Center,Department of Pathology

[5] Northwestern University,Division of Hematology and Oncology Developmental Therapeutics Institute

[6] University of Florida,Division of Hematology & Oncology, Department of Medicine

[7] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal Medical Oncology

来源：

npj Precision Oncology | / 9卷 / 1期

关键词：

D O I：

10.1038/s41698-025-00846-4

中图分类号：

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

共 50 条

[31] Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
De Stefano, Nicola
Patrono, Damiano
Colli, Fabio
Rizza, Giorgia
Paraluppi, Gianluca
Romagnoli, Renato
CANCERS, 2024, 16 (13)
[32] The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Leone, Patrizia
Solimando, Antonio Giovanni
Fasano, Rossella
Argentiero, Antonella
Malerba, Eleonora
Buonavoglia, Alessio
Lupo, Luigi Giovanni
De Re, Valli
Silvestris, Nicola
Racanelli, Vito
VACCINES, 2021, 9 (05)
[33] Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, Ambreen
D'Alessio, Antonio
Enica, Andrei
Talbot, Thomas
Fulgenzi, Claudia Angela Maria
Nteliopoulos, Georgios
Goldin, Robert D.
Cortellini, Alessio
Pinato, David J.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2022, 22 (03) : 253 - 264
[34] The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma
Cabibbo, Giuseppe
Singal, Amit G.
JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 262 - 264
[35] Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, Ann-Lii
Hsu, Chiun
Chan, Stephen L.
Choo, Su-Pin
Kudo, Masatoshi
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 307 - 319
[36] Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
Rizzo, Alessandro
Ricci, Angela Dalia
Brandi, Giovanni
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 1 - 3
[37] The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
Kim, Beom Kyung
GUT AND LIVER, 2024, 18 (01) : 3 - 4
[38] Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
Rujia Zhang
Haoran Zhao
Peng Wang
Zuoming Guo
Chunxun Liu
Zhaowei Qu
BMC Cancer, 23
[39] Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, Matthias
Scheiner, Bernhard
Pinato, David J.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (08): : 760 - 770
[40] Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
Chami, Perla
Diab, Youssef
Khalil, Danny N.
Azhari, Hassan
Jarnagin, William R.
Abou-Alfa, Ghassan K.
Harding, James J.
Hajj, Joseph
Ma, Jennifer
El Homsi, Maria
Reyngold, Marsha
Crane, Christopher
Hajj, Carla
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)

← 1 2 3 4 5 →